StockData
Genmab A/S logo

Genmab A/S (GMAB) stock

GMABNasdaqPharmaceutical PreparationsAlso trades as GNMSF
Financials through fiscal 2025, year ended Dec 31, 2025Score 0/30
$50.97−0.99 (-1.91%)

Close on Nov 18, 2026

Earnings

Genmab A/S's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q2 FY2023
4.20B DKK
EPS, Q2 FY2023
–
Latest guidance
Issued
Aug 8, 2024 · 5 items

Quarterly results

Revenue and earnings per share from each of Genmab A/S's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q2 FY2024ended Jun 30, 2024Aug 8, 2024during market hours–––Release
Q2 FY2023ended Jun 30, 2023Aug 3, 2023during market hours4.20B DKK––Release
Q2 FY2022ended Jun 30, 2022Aug 10, 2022during market hours–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Genmab A/S's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
RevenueFY202315,500 – 16,500–NewAug 3, 2023
Operating profitFY20234500 – 6000–NewAug 3, 2023
Operating expensesFY202310,400 – 10,900–NewAug 3, 2023
revenueFY202420.5 – 21.7–NewAug 8, 2024
operating profitGAAPFY20244.9 – 6.7–NewAug 8, 2024
operating profit excluding acquisition and integration related chargesnon-GAAPFY20245.3 – 7.1–NewAug 8, 2024
operating expensesGAAPFY202414.1 – 14.7–NewAug 8, 2024
operating expenses (excluding acquisition and integration related charges)non-GAAPFY202413.7 – 14.3–NewAug 8, 2024

Guidance history

Every forecast Genmab A/S put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 8, 2024operating profitFY20244.9 – 6.7New
Aug 8, 2024operating profit excluding acquisition and integration related chargesFY20245.3 – 7.1New
Aug 8, 2024operating expensesFY202414.1 – 14.7New
Aug 8, 2024operating expenses (excluding acquisition and integration related charges)FY202413.7 – 14.3New
Aug 8, 2024revenueFY202420.5 – 21.7New
Aug 3, 2023Operating profitFY20234500 – 6000New
Aug 3, 2023Operating expensesFY202310,400 – 10,900New
Aug 3, 2023RevenueFY202315,500 – 16,500New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Genmab A/S filed with the SEC as exhibits to Form 8-K or 6-K

  1. 6-K
  2. 6-K
  3. 6-K
  4. 6-K
  5. 6-K
  6. 6-K
  7. 6-K
  8. 6-K
  9. 6-K
  10. 6-K
  11. 6-K
  12. 6-K
  13. 6-K
  14. 6-K
  15. 6-K

See a number that looks wrong?